肿瘤分子靶向药物不良反应文献分析

目的:了解肿瘤分子靶向药物致不良反应(ADR)发生的特点并分析其规律,为临床合理用药提供参考。方法:检索2003年1-6月中国知网(CNKI)数据库收录的肿瘤分子靶向药物致ADR病例报道,并按患者性别、年龄、原发疾病、给药途径、ADR累及器官或系统及临床表现、分级、转归等方面进行统计、分析。结果:2 771例ADR报告中,新的ADR、严重的ADR分别有20、25例。患者年龄主要集中在41⁷0岁,最常见的临床表现为皮肤损害(占37.03%)。12种肿瘤分子靶向药物中索拉非尼引起ADR的例数居于首位,占26.84%。结论:医务人员应对肿瘤分子靶向药物引起的ADR给予重视,做到早期预防、密切监测、及时处理,减少肿瘤分子靶向药物对患者的药源性损害。

Literature Analysis of Adverse Drug Reactions Induced by Tumor Molecular-targeted Drugs

OBJECTIVE： To investigate the characteristics and regularity of adverse drug reactions （ADR） induced by tumor molecular-targeted drugs, and to provide reference for rational drug use in the clinic. METHODS： ADR cases induced by tumor mo- lecular-targeted drugs included in CNKI from Jan. to Jun. 2013 were analyzed statistically in respect of patient＇s age and sex, pri- mary diseases, route of administration, organs and systems involved in ADR and clinical manifestations, grading and outcome, etc. RESULTS： Among 2 771 ADR cases, there were 20 new ADR cases and 25 severe ADR cases. The age of patients ranged from 41 to 70 years old, and lesion of skin were the most common clinical manifestation （accounting for 37.03% ）. Among 12 kinds of targeted drugs, the incidence of ADR induced by sorafenib was the highest, accounting for 26.84%. CONCLUSIONS： Medical staff should pay attention to ADR induced by targeted drugs, early prevention, close monitoring and timely management so as to reduce the incidence of drug-induced ADR.